Evogene Establishes Highly Dilutive $2.9M ATM Offering Amidst Delisting Concerns
Summary
Evogene Ltd. launched a new At-The-Market (ATM) offering to sell up to $2.9 million in shares, representing over 40% of its market cap, as it navigates delisting threats and going concern doubts.
Key Events
-
New ATM Program Established
Evogene entered into a Sales Agreement with A.G.P./Alliance Global Partners to sell up to $2,926,500 of ordinary shares through an At-The-Market (ATM) offering.
-
Significant Potential Dilution
The maximum offering amount of $2.9 million represents over 40% of the company's current market capitalization, indicating a highly dilutive capital raise if fully utilized.
-
Context of Financial Distress
This capital raise follows recent disclosures of a Nasdaq delisting notice, substantial doubt about the company's ability to continue as a going concern, and a wider net loss in Q1 2026.
-
Utilizes Existing Shelf Registration
The shares will be issued under a shelf registration statement on Form F-3 (File No. 333-277565) that was declared effective on March 28, 2024.
Analysis
Evogene Ltd. has established an At-The-Market (ATM) offering program to sell up to $2.9 million in ordinary shares. This represents over 40% of the company's current market capitalization, indicating a highly dilutive capital raise. The company is currently facing a Nasdaq delisting notice and has previously disclosed substantial doubt about its ability to continue as a going concern, making this capital raise critical for its operational runway but at a significant cost to existing shareholders.
At the time of this filing, EVGN was trading at $0.60 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $7.2M. The 52-week trading range was $0.52 to $2.03. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.